FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311200482> ?p ?o ?g. }

• W4311200482 endingPage "2315" @default.
• W4311200482 startingPage "2298" @default.
• W4311200482 abstract "Huntingtin (HTT)-lowering therapies show great promise in treating Huntington's disease. We have developed a microRNA targeting human HTT that is delivered in an adeno-associated serotype 5 viral vector (AAV5-miHTT), and here use animal behaviour, MRI, non-invasive proton magnetic resonance spectroscopy and striatal RNA sequencing as outcome measures in preclinical mouse studies of AAV5-miHTT. The effects of AAV5-miHTT treatment were evaluated in homozygous Q175FDN mice, a mouse model of Huntington's disease with severe neuropathological and behavioural phenotypes. Homozygous mice were used instead of the more commonly used heterozygous strain, which exhibit milder phenotypes. Three-month-old homozygous Q175FDN mice, which had developed acute phenotypes by the time of treatment, were injected bilaterally into the striatum with either formulation buffer (phosphate-buffered saline + 5% sucrose), low dose (5.2 × 109 genome copies/mouse) or high dose (1.3 × 1011 genome copies/mouse) AAV5-miHTT. Wild-type mice injected with formulation buffer served as controls. Behavioural assessments of cognition, T1-weighted structural MRI and striatal proton magnetic resonance spectroscopy were performed 3 months after injection, and shortly afterwards the animals were sacrificed to collect brain tissue for protein and RNA analysis. Motor coordination was assessed at 1-month intervals beginning at 2 months of age until sacrifice. Dose-dependent changes in AAV5 vector DNA level, miHTT expression and mutant HTT were observed in striatum and cortex of AAV5-miHTT-treated Huntington's disease model mice. This pattern of microRNA expression and mutant HTT lowering rescued weight loss in homozygous Q175FDN mice but did not affect motor or cognitive phenotypes. MRI volumetric analysis detected atrophy in four brain regions in homozygous Q175FDN mice, and treatment with high dose AAV5-miHTT rescued this effect in the hippocampus. Like previous magnetic resonance spectroscopy studies in Huntington's disease patients, decreased total N-acetyl aspartate and increased myo-inositol levels were found in the striatum of homozygous Q175FDN mice. These neurochemical findings were partially reversed with AAV5-miHTT treatment. Striatal transcriptional analysis using RNA sequencing revealed mutant HTT-induced changes that were partially reversed by HTT lowering with AAV5-miHTT. Striatal proton magnetic resonance spectroscopy analysis suggests a restoration of neuronal function, and striatal RNA sequencing analysis shows a reversal of transcriptional dysregulation following AAV5-miHTT in a homozygous Huntington's disease mouse model with severe pathology. The results of this study support the use of magnetic resonance spectroscopy in HTT-lowering clinical trials and strengthen the therapeutic potential of AAV5-miHTT in reversing severe striatal dysfunction in Huntington's disease." @default.
• W4311200482 created "2022-12-24" @default.
• W4311200482 creator A5003344108 @default.
• W4311200482 creator A5003350781 @default.
• W4311200482 creator A5008746746 @default.
• W4311200482 creator A5016850505 @default.
• W4311200482 creator A5020434567 @default.
• W4311200482 creator A5028543373 @default.
• W4311200482 creator A5031187052 @default.
• W4311200482 creator A5041283105 @default.
• W4311200482 creator A5043668340 @default.
• W4311200482 creator A5044584196 @default.
• W4311200482 creator A5050951657 @default.
• W4311200482 creator A5056040604 @default.
• W4311200482 creator A5065367298 @default.
• W4311200482 creator A5074218826 @default.
• W4311200482 creator A5080522312 @default.
• W4311200482 creator A5082138079 @default.
• W4311200482 creator A5083010556 @default.
• W4311200482 creator A5088465692 @default.
• W4311200482 date "2022-12-12" @default.
• W4311200482 modified "2023-09-25" @default.
• W4311200482 title "AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model" @default.
• W4311200482 cites W1502625668 @default.
• W4311200482 cites W1730237872 @default.
• W4311200482 cites W1834161563 @default.
• W4311200482 cites W1970986383 @default.
• W4311200482 cites W1984479401 @default.
• W4311200482 cites W1985474993 @default.
• W4311200482 cites W1985911487 @default.
• W4311200482 cites W1991174366 @default.
• W4311200482 cites W1993147821 @default.
• W4311200482 cites W1997188614 @default.
• W4311200482 cites W2002644780 @default.
• W4311200482 cites W2003456064 @default.
• W4311200482 cites W2008616966 @default.
• W4311200482 cites W2010457001 @default.
• W4311200482 cites W2011178903 @default.
• W4311200482 cites W2015041659 @default.
• W4311200482 cites W2015419750 @default.
• W4311200482 cites W2015789019 @default.
• W4311200482 cites W2016390889 @default.
• W4311200482 cites W2025681964 @default.
• W4311200482 cites W2025836185 @default.
• W4311200482 cites W2026752633 @default.
• W4311200482 cites W2027367467 @default.
• W4311200482 cites W2027946127 @default.
• W4311200482 cites W2029984090 @default.
• W4311200482 cites W2030410903 @default.
• W4311200482 cites W2031417185 @default.
• W4311200482 cites W2033005054 @default.
• W4311200482 cites W2034175695 @default.
• W4311200482 cites W2034652811 @default.
• W4311200482 cites W2042739691 @default.
• W4311200482 cites W2053984362 @default.
• W4311200482 cites W2060148506 @default.
• W4311200482 cites W2062682951 @default.
• W4311200482 cites W2068422066 @default.
• W4311200482 cites W2073466689 @default.
• W4311200482 cites W2082056883 @default.
• W4311200482 cites W2082501455 @default.
• W4311200482 cites W2088410491 @default.
• W4311200482 cites W2089975325 @default.
• W4311200482 cites W2096884057 @default.
• W4311200482 cites W2106334429 @default.
• W4311200482 cites W2107514471 @default.
• W4311200482 cites W2113576511 @default.
• W4311200482 cites W2113661629 @default.
• W4311200482 cites W2114104545 @default.
• W4311200482 cites W2118546680 @default.
• W4311200482 cites W2121642311 @default.
• W4311200482 cites W2124017140 @default.
• W4311200482 cites W2134401364 @default.
• W4311200482 cites W2138658288 @default.
• W4311200482 cites W2139670783 @default.
• W4311200482 cites W2143116460 @default.
• W4311200482 cites W2143760278 @default.
• W4311200482 cites W2146512944 @default.
• W4311200482 cites W2157203036 @default.
• W4311200482 cites W2158174988 @default.
• W4311200482 cites W2164413723 @default.
• W4311200482 cites W2168710204 @default.
• W4311200482 cites W2169456326 @default.
• W4311200482 cites W2170256902 @default.
• W4311200482 cites W2188519171 @default.
• W4311200482 cites W2291779372 @default.
• W4311200482 cites W2323582185 @default.
• W4311200482 cites W2463691924 @default.
• W4311200482 cites W2474748733 @default.
• W4311200482 cites W2509688377 @default.
• W4311200482 cites W2522187793 @default.
• W4311200482 cites W2574064466 @default.
• W4311200482 cites W2623948558 @default.
• W4311200482 cites W2743117620 @default.
• W4311200482 cites W2749718288 @default.
• W4311200482 cites W2767946212 @default.
• W4311200482 cites W2768840488 @default.
• W4311200482 cites W2811325414 @default.

• next